Diabetes Canada Clinical Practice Guidelines Expert Committee

Vera Bril MD, FRCPC, Ari Breiner MD, FRCPC, Bruce A. Perkins MD, MPH, FRCPC, Douglas Zochodne MD, FRCPC

  • Key Messages
  • Recommendations
  • Figures
  • Full Text
  • References

Key Messages

  • Elevated blood glucose levels, elevated triglycerides, high body mass index, smoking and hypertension are risk factors for neuropathy.
  • Intensive glycemic control is effective for the primary prevention or secondary intervention of neuropathy in people with type 1 diabetes.
  • In people with type 2 diabetes, lower blood glucose levels are associated with a reduced frequency of neuropathy.
  • Simple physical examination screening tests, such as the 10 g monofilament (on the dorsal aspect of the great toe bilaterally) and vibration perception (with 128 Hz tuning fork), perform reasonably well for the identification of neuropathy and prediction of its future onset.

Key Messages for People with Diabetes

  • Exposure to high blood glucose levels over an extended period of time can cause diabetic peripheral neuropathy or damage to the nerves that go to the feet, legs and, when markedly advanced, to the hands and arms.
  • The most common symptoms of diabetic peripheral neuropathy are loss of sensations in the toes and feet, and presence of symptoms, such as sharp shooting pains, burning, tingling, a feeling of being pricked with pins, throbbing and numbness.
  • Diabetic peripheral neuropathy increases the risk for foot ulcers and amputation.
  • Your health-care provider or foot care specialist can test for diabetic peripheral neuropathy by lightly pressing a thin nylon rod (10 g monofilament) and by using the 128 Hz tuning fork on the top surface of your big toe.
  • Although there is no cure, there are many ways you can effectively manage diabetic peripheral neuropathy, including:
    • Proper foot care, including daily foot inspection
    • Effective blood glucose control
    • Medications that may help with nerve pain
  • Diabetic autonomic neuropathies affect the part of the nervous system responsible for control of internal body functions and may target the heart (cardiac autonomic neuropathy), gastrointestinal tract, and genitourinary system, and can cause sexual dysfunction.


Diabetes is the leading cause of neuropathy in North America (1). Estimates of the prevalence vary depending on the diagnostic criteria and population studied. A reasonable figure based on several large studies is that detectable sensorimotor polyneuropathy (diffuse and symmetric neuropathy) will develop within 10 years of the onset of diabetes in 40% to 50% of people with type 1 (1–3) and type 2 diabetes (4–6). While clinical neuropathy is uncommon in people with type 1 diabetes within the first 5 years after the onset of diabetes, people with type 2 diabetes may have neuropathy at the time of diagnosis or even in the prediabetes stage (4–7). Risk factors for neuropathy include elevated blood glucose (BG) levels, elevated triglycerides (TG), high body mass index (BMI), smoking and hypertension (8). There appear to be multifactorial mechanisms behind the pathogenesis of diabetic neuropathy (9) and it may represent a unique form of neurodegeneration (9,10).

The most common form of diabetic neuropathy is distal symmetric polyneuropathy (DSPN). Symptoms vary according to the class of sensory fibres involved. The most common early symptoms are from small fibre involvement and include pain (e.g. sharp, shooting) and dysesthesias (e.g. burning). Pain may be present in the presence of a normal clinical examination and normal nerve conduction studies, which are a measure of large fibre function (11). The involvement of large fibres may cause numbness, tingling and loss of protective sensation.

Neuropathic pain is frequently bothersome and often limits physical activity, quality of life and work productivity (3,11–13). Additionally, people with neuropathy utilize more health resources than those without (14). Foot ulceration, which depends on the degree of foot insensitivity (15), and amputation are important and costly sequelae of diabetic neuropathy (16).

Diabetic autonomic neuropathies (DAN) affect the autonomic neurons and may target the innervation of the heart (cardiac autonomic neuropathy [CAN]), gastrointestinal tract, genitourinary system, sexual function, pupillary responses and sweating. Specialized laboratories that study clinical autonomic disorders, including DAN, are available at some centres (17).

The prevalence of CAN increases with diabetes duration in people with type 1 and type 2 diabetes. In the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) study, prevalence rates of at least 30% were observed after 20 years of type 1 diabetes (2,18). CAN may be present in up to 60% of people with type 2 diabetes after 15 years (19). CAN may be identified by heart rate variability and has been shown to be a risk factor for mortality in diabetes (20–22); however, further study is required to determine if interventions are helpful in reducing the risk of subsequent cardiac events and mortality.

Other features of CAN are postural hypotension, and resting tachycardia (i.e. 100 beats/min). For postural hypotension, the diagnosis is made by measuring supine, followed by a 1-minute standing blood pressure (BP) and pulse. A fall of greater than 20 mmHg systolic without an appropriate increase in heart rate is significant. Treatment includes conservative measures to increase fluid and salt intake, caution with exacerbating medications, compression stockings and sleeping with the head of the bed elevated. Specific therapies include fludrocortisone, midodrine and droxidopa (approved in the United States but not Canada), with care taken to monitor for supine hypertension (10,23,24).

Gastrointestinal neuropathies may be associated with gastroparesis, constipation, diarrhea (especially nocturnal), and incontinence. A gastric emptying study may be helpful in diagnosis. Treatment approaches include dietary measures, withdrawal of exacerbating medications (e.g. glucagon-like peptide-1 [GLP-1] receptor agonists, opioids) and, in severe instances, temporary use of the prokinetic agent, metoclopramide, but its use is limited by risk of extrapyramidal side effects.

Bladder dysfunction in DAN includes loss of bladder sensation and later detrusor dysfunction with overflow incontinence, predisposition to infection and inability to empty. Bladder function should be evaluated in people with diabetes with recurrent urinary tract infections, pyelonephritis or incontinence. The use of amitriptyline is contraindicated in people with diabetic bladder involvement owing to potential anticholinergic side effects.

Erectile dysfunction in men is the most common symptom of DAN with a prevalence of up to 40% (25), although it may be associated with the presence or the absence of DSPN. Treatment includes phosphodiesterase-5 inhibitors for mild erectile dysfunction, local prostaglandin injections, vacuum devices or prostheses (see Sexual Dysfunction and Hypogonadism in Men with Diabetes chapter, p. S228).

Sudomotor abnormalities are loss of sweating in the extremities with inappropriate truncal sweating, dry skin or heat intolerance. Gustatory sweating may occur and consists of excessive sweating in the head and neck triggered by food consumption or the smell of food.

Mononeuropathies, or focal neuropathies, can occur with involvement of the median, ulnar, radial and common peroneal nerves. Carpal tunnel syndrome and ulnar neuropathy at the elbow is also common in diabetes and can be distinguished from polyneuropathy by electrophysiological studies (26).

There are other forms of diabetic-related neuropathy that are less common, such as diabetic radiculoplexus neuropathy (also known as diabetic amyotrophy or diabetic polyradiculoneuropathy), cranial neuropathies (primarily involving cranial nerves III, IV, VI, and VII), thoracic radiculopathy and others (27). Diabetes may also target other parts of the nervous system, including the brain (28).

The underdiagnosis of neuropathy is a fundamental problem in the primary care of people with diabetes and impedes the benefits of early identification, the management necessary to achieve improved glycemic control and the prevention of neuropathy-related sequelae (29). However, it is important to exclude other causes of neuropathy besides diabetes by way of obtaining a family and medication (including alcohol) history. Relevant investigations may include: serum B12 (particularly with use of metformin), folic acid, thyroid function, complete blood count, serum creatinine and protein electrophoresis.

Screening for Peripheral Neuropathy

Asymptomatic screening for neuropathy can be performed rapidly and reliably using the 10 g Semmes-Weinstein monofilament or the 128 Hz tuning fork over the dorsal aspect of the great toe bilaterally (30–34). Other screening tests can include pinprick or temperature (starting distally bilaterally and moving proximally until a sensory threshold is identified) and ankle reflexes. Methods for using the monofilament or tuning fork to detect diabetic neuropathy are outlined in Appendix 11A. Rapid Screening for Diabetic Neuropathy Using the 10 g Semmes-Weinstein Monofilament, and Appendix 11B. Rapid Screening for Diabetic Neuropathy Using the 128 Hz Vibration Tuning Fork (30,31,34). Additionally, several clinical scoring systems based on composite measures of symptoms and signs have been developed and evaluated for identification of neuropathy, but it is not clear if these more complex procedures have benefit over simplified screening tests for neuropathy identification. Evaluation for neuropathy in the lower limbs should also accompany the evaluation of vascular supply and skin integrity as outlined in the Foot Care chapter, p. S222. In addition, it is important to recognize that the 10 g monofilament test for annual DSPN screening is different than the testing used to identify a foot at high risk for ulceration in the context of recognized neuropathy. Testing to assess risk for foot ulceration generally requires testing of 3 sites on each foot (see Appendix 12: Monofilament Testing in the Diabetic Foot, p. S322).

Individuals with asymmetrical manifestations of neuropathy, greater motor than sensory impairments, or rapidly progressive symptoms or signs of neuropathy may have nondiabetic causes of neuropathy that may require more careful evaluation, and referral for additional neurological evaluation should be considered.

Table 1
Treatment options for the management of painful diabetic peripheral neuropathy
BID, 2 times a day; OD, once daily; QHS, every bedtime; QID, 4 times a day.
Dose ranges are for adults and are taken from published trials—smaller starting doses and slower titration schedules may be indicated. Optimal doses are the lowest doses required for maximum efficacy without significant side effects. Although required for some agents, dose adjustments for renal and liver dysfunction are not shown here. Physicians should refer to the most current edition of the Compendium of Pharmaceuticals and Specialties (Canadian Pharmacists Association, Ottawa, Ontario, Canada) for product monographs and complete prescribing information.
*Use with caution due to risks of dependency and tolerance; not advised as first-line therapy, and generally considered a treatment of last resort for painful neuropathy.
Denotes that this drug is not currently approved by Health Canada for the management of neuropathic pain associated with diabetic peripheral neuropathy.
  Suggested starting dose Suggested titration if tolerated Suggested maximal tolerated dose Estimated monthly cost for starting dose
Amitriptyline (56,57,61,72) 10 mg QHS May titrate slowly up to 100 mg po qhs 150 mg/day $14.49 (30)
Duloxetine (60,64) 30 mg OD May titrate to 60 mg po od 120 mg/day $28.22 (30)
Venlafaxine (62,63,75–79) 37.5 mg BID May titrate slowly up to 150 mg po bid 300 mg/day $23.16 (60)
Note: Although the following agents have demonstrated efficacy for neuropathic pain, their use should be selective, after other options have failed to be effective, and clinicians must be aware of the risks of tolerance, abuse, dependency and addiction (45). The limited use of these agents should follow the principles of the 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain (54).
Tramadol (44)* 50 mg QID May titrate slowly up to 50 mg po qid 400 mg/day $100.45 (120)
Tapentadol ER (40)* 100 mg BID May titrate slowly up to 250 mg po bid 250 mg po bid $118.49 (60)
Dextromethorphan (42)* 100 mg QID May titrate slowly up to 200 mg po qid 960 mg/day requires compounding of the capsules
Morphine sustained release (74)* 15 mg BID May titrate slowly up to 60 mg po bid 180 mg/day $27.61 (60)
Oxycodone ER (43)* 10 mg BID May titrate slowly up to 40 mg po bid 160 mg/day $42.60 (60)
Topical nitrate sprays (65,66,70) 30 mg spray to legs QHS May titrate slowly up to 30 mg spray to legs bid 60 mg/day  
Capsaicin cream (68,69)** 0.075% cream applied 3–4 times per day May titrate to 5–6 times per day 5–6 applications per day $17.99
Transcutaneous electrical nerve stimulation - - - -

Management of Diabetic Neuropathy

Intensive glycemic control is effective for the primary prevention and secondary intervention of neuropathy in people with type 1 diabetes (3,6,35,36). In fact, the benefits of intensive insulin treatment persist for over a decade for the primary prevention of neuropathy (37). In those with type 2 diabetes, target BG levels are associated with a reduced frequency of neuropathy (5,12,38). No other clearly efficacious disease-modifying treatments are currently available. Multiple treatments are available for the management of neuropathic pain, and detailed evidence-based guidelines on the treatment of painful diabetic neuropathy (PDN) have been published (39). An important observation is that few people have complete relief of painful symptoms with any treatment, and that a 30% to 50% reduction in baseline pain, usually measured by a visual analogue scale of 0 to 10 out of 10 maximal pain intensity, is considered to be a clinically meaningful response.

There are insufficient comparative studies to recommend which oral medication should be used first line, although the primary use of opioids for PDN, despite clinical trial evidence for pain efficacy (40–44), is not recommended due to the potential for dependency, tolerance, dose escalation and diversion (39,45). Anticonvulsants (46–54) and antidepressants (55–64) are most commonly used as first-line therapy. Details are listed in Table 1. Pregabalin and duloxetine have received approval for the treatment of neuropathic pain in diabetes by Health Canada.

Other effective therapeutic options include topical nitrate sprays (65,66), topical capsaicin (67–70) and transcutaneous electrical nerve stimulation (71,72). However, effective treatment with capsaicin involves short-term pain that limits its acceptability and generalizability in clinical practice. The surgical release of distal lower limb nerves is not recommended due to lack of evidence supporting efficacy (73) and the possible complications of foot and ankle surgery in people with diabetes.

Dose ranges for painful neuropathic symptoms described in Table 1 are for adults and are taken from published trials; smaller starting doses and slower titration schedules may be indicated. Optimal doses are the lowest doses required for maximum efficacy without significant side effects. Although required for some agents, dose adjustments for renal and hepatic dysfunction are not shown here. Physicians should refer to the most current edition of the Compendium of Pharmaceuticals and Specialties (Canadian Pharmacists Association, Ottawa, Ontario, Canada) for product monographs and complete prescribing information.



Denotes that this drug is not currently approved by Health Canada for the management of neuropathic pain associated specifically with diabetic peripheral neuropathy.

Most studies failed to achieve Grade A, Level 1 due to a <80% completion rate (39).


A1C, glycated hemoglobin; BG, blood glucose; BMI, body mass index; CAD, cardiac autonomic neuropathy; DAN, diabetic autonomic neuropathy; DPN, diabetic peripheral neuropathy; PDN, painful diabetic neuropathy.

  1. In people with type 2 diabetes, screening for peripheral neuropathy should begin at diagnosis of diabetes and occur annually thereafter [Grade D, Consensus]. In people with type 1 diabetes, annual screening should commence after 5 years' post-pubertal duration of diabetes [Grade D, Consensus].
  2. Screening for peripheral neuropathy should be conducted by assessing loss of sensitivity to the 10 g monofilament or loss of sensitivity to vibration at the dorsum of the great toe [Grade A, Level 1 (31,34)] (see Appendices 11A and 11B. Rapid Screening for Diabetic Neuropathy).
  3. People with diabetes should be treated with intensified glycemic control to prevent the onset and progression of neuropathy [Grade A, Level 1A (3,35) for type 1 diabetes; Grade B, Level 2 (38) for type 2 diabetes].
  4. The following agents may be used alone or in combination for relief of painful peripheral neuropathy:
    • Anticonvulsants (pregabalin [Grade A, Level 1 (47,52)], gabapentin [Grade B, Level 2 (46,74)], valproate [Grade B, Level 2 (50,51)]
    • Antidepressants (amitriptyline, duloxetine, venlafaxine) [Grade B, Level 2 (56,57,60,61,63,75)]

    • Topical nitrate spray [Grade B, Level 2 (65,66,70)]

    • In people not responsive to the above agents, opioid analgesics (tramadol, tapentadol ER, oxycodone ER) may be used [Grade B, Level 2 (41,43,44)]. Prescribers should be cautious due to risks of abuse, dependency and tolerance, and follow the recommendations of the 2017 Canadian Guidelines for Opioids for Chronic Non-Cancer Pain (54) [Grade D, Consensus].

Literature Review Flow Diagram for Chapter 31: Neuropathy

*Excluded based on: population, intervention/exposure, comparator/control or study design

From reference 80.

For more information, visit

Author Disclosures

Dr. Bril reports grants from Pfizer and Lilly, during the conduct of the study; and other support from Pfizer, outside the submitted work. Dr. Breiner reports grants from GBS-CIDP Foundation International, Grifols, Inc, and other support from Pfizer, outside the submitted work. No other authors have anything to disclose.


  1. P.J.DyckK.M.KratzJ.L.KarnesThe prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester diabetic neuropathy studyNeurology431993817824
  2. C.L.MartinJ.W.AlbersR.Pop-BusuiNeuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications studyDiabetes Care3720143138
  3. Diabetes Control and Complications Trial Research GroupD.M.NathanS.GenuthThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research groupN Engl J Med3291993977986
  4. R.Pop-BusuiLuJ.M.M.BrooksImpact of glycemic control strategies ontheprogressionofdiabeticperipheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohortDiabetes Care36201332083215
  5. F.Ismail-BeigiT.CravenM.A.BanerjiEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trialLancet3762010419430
  6. L.AngM.JaiswalC.MartinGlucose control and diabetic neuropathy: Lessons from recent large clinical trialsCurr Diab Rep142014115
  7. J.R.SingletonA.G.SmithM.B.BrombergIncreased prevalence of impaired glucose tolerance in patients with painful sensory neuropathyDiabetes Care24200114481453
  8. S.TesfayeN.ChaturvediS.E.EatonVascular risk factors and diabetic neuropathyN Engl J Med3522005341350
  9. B.C.CallaghanChengH.T.C.L.StablesDiabetic neuropathy: Clinical manifestations and current treatmentsLancet Neurol112012521534
  10. American Diabetes AssociationADA: Standards of medical care in diabetes 2017Diabetes Care402017S51135
  11. A.I.VinikClinical Practice. Diabetic sensory and motor neuropathyN Engl J Med374201614551464
  12. J.PartanenL.NiskanenJ.LehtinenNatural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitusN Engl J Med33319958994
  13. American Diabetes Association (ADA)8. Pharmacologic approaches to glycemic treatment in the ADA: Standards of medical care in diabetes 2017Diabetes Care201740
  14. M.daCosta DiBonaventuraJ.C.CappelleriA.V.JoshiA longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and costPain Med122011118126
  15. M.J.YoungJ.L.BreddyA.VevesThe prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective studyDiabetes Care171994557560
  16. G.E.ReiberE.J.BoykoD.G.SmithLower extremity foot ulcers and amputations in diabetes. Diabetes in America2nd edn1985National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney DiseasesBethesda409428
  17. D.DabeleaJ.M.StaffordE.J.Mayer-DavisAssociation of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthoodJAMA3172017825835
  18. R.Pop-BusuiP.A.LowB.H.WaberskiEffects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC)Circulation119200928862893
  19. P.A.LowL.M.Benrud-LarsonD.M.SlettenAutonomic symptoms and diabetic neuropathy: A population-based studyDiabetes Care27200429422947
  20. R.Pop-BusuiG.W.EvansH.C.GersteinEffects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDiabetes Care33201015781584
  21. R.Pop-BusuiB.H.BraffettB.ZinmanCardiovascular autonomic neuropathy and cardiovascular outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyDiabetes Care40201794100
  22. S.S.Soedamah-MuthuN.ChaturvediD.R.WitteRelationship between risk factors and mortality in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study (PCS)Diabetes Care31200813601366
  23. R.FreemanClinical practice. Neurogenic orthostatic hypotensionN Engl J Med3582008615624
  24. P.A.LowJ.L.GildenR.FreemanEfficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study GroupJAMA277199710461051
  25. C.G.BaconHuF.B.E.GiovannucciAssociation of type and duration of diabetes with erectile dysfunction in a large cohort of menDiabetes Care25200214581463
  26. B.A.PerkinsD.OlaleyeV.BrilCarpal tunnel syndrome in patients with diabetic polyneuropathyDiabetes Care252002565569
  27. R.Pop-BusuiA.J.BoultonE.L.FeldmanDiabetic neuropathy: A position statement by the American Diabetes AssociationDiabetes Care402017136154
  28. D.W.ZochodneR.A.MalikDiabetes and the nervous systemD.ZochodneR.MalikHandbook of Clinical Neuroloty2014Elsevier B.V.2615
  29. W.H.HermanL.KennedyUnderdiagnosis of peripheral neuropathy in type 2 diabetesDiabetes Care28200514801481
  30. J.N.KanjiR.E.AnglinD.L.HuntDoes this patient with diabetes have large-fiber peripheral neuropathy?JAMA303201015261532
  31. B.A.PerkinsD.OlaleyeB.ZinmanSimple screening tests for peripheral neuropathy in the diabetes clinicDiabetes Care242001250256
  32. S.J.Rith-NajarianT.StoluskyD.M.GohdesIdentifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteriaDiabetes Care15199213861389
  33. M.RahmanS.J.GriffinW.RathmannHow should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measuresDiabet Med202003368374
  34. B.A.PerkinsA.OrszagM.NgoPrediction of incident diabetic neuropathy using the monofilament examination: A 4-year prospective studyDiabetes Care33201015491554
  35. P.ReichardB.BerglundA.BritzIntensified conventional insulin treatment retards the microvascular complications of Insulin-Dependent Diabetes Mellitus (IDDM): The Stockholm Diabetes Intervention Study (SDIS) after 5 yearsJ Intern Med2301991101108
  36. The Diabetes Control and Complications Trial Research GroupThe effect of intensive diabetes therapy on the development and progression of neuropathyAnn Intern Med1221995561568
  37. J.W.AlbersW.H.HermanR.Pop-BusuiEffect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) StudyDiabetes Care33201010901096
  38. UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet3521998837853
  39. V.BrilJ.EnglandG.M.FranklinEvidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationNeurology76201117581765
  40. S.SchwartzM.EtropolskiD.Y.ShapiroSafety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trialCurr Med Res Opin272011151162
  41. SangC.N.S.BooherI.GilronDextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trialsAnesthesiology96200210531061
  42. K.A.NelsonK.M.ParkE.RobinovitzHigh-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgiaNeurology48199712121218
  43. J.S.GimbelP.RichardsR.K.PortenoyControlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trialNeurology602003927934
  44. Y.HaratiC.GoochM.SwensonDouble-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathyNeurology50199818421846
  45. L.ManchikantiA.SinghTherapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioidsPain Physician112008S63S88
  46. M.BackonjaA.BeydounK.R.EdwardsGabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trialJAMA280199818311836
  47. R.W.RichterR.PortenoyU.SharmaRelief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trialJ Pain62005253260
  48. H.LesserU.SharmaL.LaMoreauxPregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trialNeurology63200421042110
  49. J.RosenstockM.TuchmanL.LaMoreauxPregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trialPain1102004628638
  50. D.K.KocharN.JainR.P.AgarwalSodium valproate in the management of painful neuropathy in type 2 diabetes—a randomized placebo controlled studyActa Neurol Scand1062002248252
  51. D.K.KocharN.RawatR.P.AgrawalSodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled studyQJM9720043338
  52. GuanY.DingX.ChengY.Efficacy of pregabalin for peripheral neuropathic pain: Results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in ChinaClin Ther332011159166
  53. J.SatohS.YagihashiM.BabaEfficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: A 14 week, randomized, double-blind, placebo-controlled trialDiabet Med282011109116
  54. The 2017 Canadian guideline for opioids for chronic non-cancer pain2017McMaster University: National Pain CentreHamilton
  55. H.YasudaN.HottaK.NakaoSuperiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in JapanJ Diabetes Investig22011132139
  56. M.B.MaxM.CulnaneS.C.SchaferAmitriptyline relieves diabetic neuropathy pain in patients with normal or depressed moodNeurology371987589596
  57. M.B.MaxS.A.LynchJ.MuirEffects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathyN Engl J Med326199212501256
  58. D.J.GoldsteinLuY.M.J.DetkeDuloxetine vs. placebo in patients with painful diabetic neuropathyPain1162005109118
  59. J.RaskinT.R.SmithK.WongDuloxetine versus routine care in the long-term management of diabetic peripheral neuropathic painJ Palliat Med920062940
  60. J.RaskinY.L.PritchettWangF.A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painPain Med62005346356
  61. J.F.WernickeY.L.PritchettD.N.D'SouzaA randomized controlled trial of duloxetine in diabetic peripheral neuropathic painNeurology67200614111420
  62. M.C.RowbothamV.GoliN.R.KunzVenlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled studyPain1102004697706
  63. A.K.KadirogluD.SitH.KayabasiThe effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitusJ Diabetes Complications222008241245
  64. H.KaurD.HotaA.BhansaliA comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: A randomized, double-blind, cross-over clinical trialDiabetes Care342011818822
  65. R.P.AgrawalR.ChoudharyP.SharmaGlyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over studyDiabetes Res Clin Pract772007161167
  66. K.C.YuenN.R.BakerG.RaymanTreatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: A double-blind placebo-controlled cross-over studyDiabetes Care25200216991703
  67. P.A.LowT.L.Opfer-GehrkingP.J.DyckDouble-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathyPain621995163168
  68. The Capsaicin Study GroupTreatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled studyArch Intern Med151199122252229
  69. R.TandanG.A.LewisP.B.KrusinskiTopical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-upDiabetes Care151992814
  70. R.P.AgrawalJ.GoswamiS.JainManagement of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled studyDiabetes Res Clin Pract832009371378
  71. E.BosiM.ContiC.VermigliEffectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathyDiabetologia482005817823
  72. D.KumarM.S.AlvaroI.S.JulkaDiabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic reliefDiabetes Care21199813221325
  73. Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyV.ChaudhryJ.C.StevensPractice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology66200618051808
  74. I.GilronJ.M.BaileyTuD.Morphine, gabapentin, or their combination for neuropathic painN Engl J Med352200513241334
  75. S.TesfayeS.WilhelmA.LledoDuloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic painPain154201326162625
  76. E.O.UdoN.M.van HemelN.P.ZuithoffRisk of heart failure- and cardiac death gradually increases with more right ventricular pacingInt J Cardiol185201595100
  77. W.J.ElliottJ.WhitmoreJ.D.FeldsteinEfficacy and safety of perindopril arginine + amlodipine in hypertensionJ Am Soc Hypertens92015266274
  78. R.NishimuraY.TanakaK.KoiwaiEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, 4-week studyCardiovasc Diabetol14201511
  79. ChenD.Y.WangS.H.MaoC.T.Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort studyInt J Cardiol1812015200206
  80. D.MoherA.LiberatiJ.TetzlaffPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statementPLoS Med62009e1000097
Reproduced with permission from Canadian Journal of Diabetes © 2018 Canadian Diabetes Association. To cite this article, please refer to For citation.

*The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. All content on, CPG Apps and in our online store remains exactly the same. For questions, contact